In light of these findings, we have developed an off-the-shelf cell product consisting of engineered NK cells expressing a second-generation CAR directed against CD123 (CAR.CD123-NK cells), designed to enhance NK-cell antitumour effects in AML patients and to reduce unwanted toxicity. This evidence concerns the gene IL3RA and acute myeloid leukemia.